WallStreetZenWallStreetZen

NYSE: OGN
Organon & Co Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Organon & Co earnings were $864.0M for the trailing 12 months ending Dec 31, 2024, with -16.2% growth year over year. The latest OGN earnings report on Dec 31, 2024 announced Q4 2024 earnings of $109.0M, down 69.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, OGN reported annual earnings of $864.0M, with -15.5% growth. The next OGN earnings date is Apr 30, 2025.

OGN past earnings growth

How has OGN's earnings growth performed historically?

Company
-16.21%
Industry
355.71%
Market
62.9%
OGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
OGN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
OGN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

OGN earnings history

Current Revenue
$6.4B
Current Earnings
$864.0M
Current Profit Margin
13.5%

OGN Return on Equity

Current Company
298.7%
Current Industry
40.7%
Current Market
34.1%
OGN's Return on Equity (298.7%)... subscribe to Premium to read more.
High Return on Equity Performance

OGN undefined

Current Company
6.9%
Current Industry
8.3%
OGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when OGN announces earnings.

OGN undefined

Current Company
12.78%
Current Industry
14.7%
OGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

OGN vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
OGN$1.60B$864.00M-23.34%$3.36
GRFS$1.71B$174.36M-25.16%$0.26
AMRN-$74.18M-$82.18MN/A-$4.00
SCLX-$66.08M-$72.81MN/A-$19.60
MIRA-$8.02M-$7.85MN/A-$0.51
View Top General Drug Manufacturer Stocks

OGN earnings dates

Next earnings date
Apr 30, 2025

Organon & Co Earnings Reports & History FAQ

What were Organon & Co's earnings last quarter?

On OGN's earnings call on Invalid Date, Organon & Co (NYSE: OGN) reported Q4 2024 earnings per share (EPS) of $0.42, up 80.37% year over year. Total OGN earnings for the quarter were $109.00 million. In the same quarter last year, Organon & Co's earnings per share (EPS) was $2.14.

If you're new to stock investing, here's how to buy Organon & Co stock.

When does Organon & Co report earnings?

The next OGN earnings call is Invalid Date. Add OGN to your watchlist to be reminded of Organon & Co's next earnings date.

Is Organon & Co profitable or losing money?

As of the last Organon & Co earnings report, Organon & Co is currently profitable. Organon & Co's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $864.00 million, a 15.54% decrease year over year.

What was OGN's earnings growth in the past year?

As of Organon & Co's earnings date in Invalid Date, Organon & Co's earnings has grown -16.21% year over year. This is 371.92 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 355.71%. OGN earnings in the past year totalled $864.00 million.

What are Organon & Co's earnings expectations?

The current EPS estimate for Organon & Co's earnings report in Invalid Date is $1.01.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.